BRAF and neoplasm: Hence, we sought to exploit the glycolytic dependency of BRAF-driven tumours as a metabolic vulnerability and to adopt new therapeutic approaches to maximise drug efficacy (even at low doses) and avoid—or delay—the onset of secondary resistance and drug-related toxicity.